Pharmesis International Ltd. BFK.SI Stock
Pharmesis International Ltd. Price Chart
Pharmesis International Ltd. BFK.SI Financial and Trading Overview
Pharmesis International Ltd. stock price | 0.08 SGD |
Previous Close | 0.15 SGD |
Open | 0.14 SGD |
Bid | 0.1 SGD x 0 |
Ask | 0.15 SGD x 0 |
Day's Range | 0.14 - 0.15 SGD |
52 Week Range | 0.08 - 0.15 SGD |
Volume | 2.5K SGD |
Avg. Volume | 737 SGD |
Market Cap | 4M SGD |
Beta (5Y Monthly) | -0.127586 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.01 SGD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
BFK.SI Valuation Measures
Enterprise Value | 3.21M SGD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.07945363 |
Price/Book (mrq) | 0.061860062 |
Enterprise Value/Revenue | 0.064 |
Enterprise Value/EBITDA | -2.7 |
Trading Information
Pharmesis International Ltd. Stock Price History
Beta (5Y Monthly) | -0.127586 |
52-Week Change | 57.60% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.15 SGD |
52 Week Low | 0.08 SGD |
50-Day Moving Average | 0.12 SGD |
200-Day Moving Average | 0.11 SGD |
BFK.SI Share Statistics
Avg. Volume (3 month) | 737 SGD |
Avg. Daily Volume (10-Days) | 0 SGD |
Shares Outstanding | 27.6M |
Float | 6.17M |
Short Ratio | N/A |
% Held by Insiders | 77.23% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:10 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -7.068% |
Operating Margin (ttm) | -5.019% |
Gross Margin | 47.66% |
EBITDA Margin | -2.36% |
Management Effectiveness
Return on Assets (ttm) | -1.65% |
Return on Equity (ttm) | -5.42% |
Income Statement
Revenue (ttm) | 50.37M SGD |
Revenue Per Share (ttm) | 2.19 SGD |
Quarterly Revenue Growth (yoy) | 14.39% |
Gross Profit (ttm) | 24.01M SGD |
EBITDA | -1190000 SGD |
Net Income Avi to Common (ttm) | -3560000 SGD |
Diluted EPS (ttm) | -0.03 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 19.72M SGD |
Total Cash Per Share (mrq) | 0.86 SGD |
Total Debt (mrq) | 16.53M SGD |
Total Debt/Equity (mrq) | 29.02 SGD |
Current Ratio (mrq) | 1.115 |
Book Value Per Share (mrq) | 2.344 |
Cash Flow Statement
Operating Cash Flow (ttm) | 6.56M SGD |
Levered Free Cash Flow (ttm) | 7.33M SGD |
Profile of Pharmesis International Ltd.
Country | Singapore |
State | N/A |
City | Singapore |
Address | 5 Kallang Sector #03-02 |
ZIP | 349279 |
Phone | 65 6846 0766 |
Website | https://www.pharmesis.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Pharmesis International Ltd., an investment holding company, research, develops, produces, packages, sells, and markets western medicines and traditional Chinese medicine (TCM) formulated products for hospitals and medical institutions in the People's Republic of China. The company provides prescribed products and over-the-counter drugs. It offers western medicine products under the Kinna brand, including Anethole Trithione for the treatment of illness relating to the liver and gall bladder; Compound Procaine hydrochloride to treat arteriosclerosi, menopausal symptoms, dyspepsia, and adynamia; Lianpushuangqing for acute inflammation; AFenKa to treat migraine, pain, headache, nasosinusitis, cold, muscle pain, menstrual pain, toothache, and arthritis; Xiao Shi Jian Pi to treat flatus, inappetency, dyspepsy, and spleen weakness; and Xiao Luo Tong for the rheumatoid arthritis and other rheumatic diseases treatment. The company also provides TCM formulated products under the Longlife brand name comprising Gulin Gansu for acute and chronic hepatitis treatment; Er Ding granules to treat jaundice, and clear heat and toxics; and Kang Gu Zeng Sheng for boosting the functions of kidney, as well as for increasing blood circulation and alleviating pain. In addition, it offers health supplement products, such as Mei Li Wei Ta to combat aging process and support bone health for women; Hao Xiu Xi to enhance sleep and regulate blood fats; Hao Zhuang Tai to regulate blood fats and fight fatique; and Qianlieman'an for promoting healthy prostate function and colon health, and supporting urinary function, as well as SHULINGHOU for the treatment of acute and chronic pharyngitis, laryngitis, sore throat, and hoarseness. Further, the company engages in the wholesale of chemical drugs, biological raw products, TCM products, antibiotics, and antibiotic agents. Pharmesis International Ltd. was founded in 1996 and is based in Singapore.
Q&A For Pharmesis International Ltd. Stock
What is a current BFK.SI stock price?
Pharmesis International Ltd. BFK.SI stock price today per share is 0.08 SGD.
How to purchase Pharmesis International Ltd. stock?
You can buy BFK.SI shares on the SES exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Pharmesis International Ltd.?
The stock symbol or ticker of Pharmesis International Ltd. is BFK.SI.
Which industry does the Pharmesis International Ltd. company belong to?
The Pharmesis International Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Pharmesis International Ltd. have in circulation?
The max supply of Pharmesis International Ltd. shares is 27.6M.
What is Pharmesis International Ltd. Price to Earnings Ratio (PE Ratio)?
Pharmesis International Ltd. PE Ratio is now.
What was Pharmesis International Ltd. earnings per share over the trailing 12 months (TTM)?
Pharmesis International Ltd. EPS is -0.01 SGD over the trailing 12 months.
Which sector does the Pharmesis International Ltd. company belong to?
The Pharmesis International Ltd. sector is Healthcare.